NeOnc Technologies Holdings, Inc. (NTHI)
NASDAQ: NTHI · Real-Time Price · USD
3.500
-0.490 (-12.28%)
At close: Jun 27, 2025, 4:00 PM
3.680
+0.180 (5.14%)
After-hours: Jun 27, 2025, 4:04 PM EDT
NTHI Employees
NeOnc Technologies Holdings had 8 employees as of December 31, 2023.
Employees
8
Change
n/a
Growth
n/a
Revenue / Employee
$9,999
Profits / Employee
-$5,870,184
Market Cap
66.59M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 8 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
NTHI News
- 21 days ago - NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs - GlobeNewsWire
- 2 months ago - NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets - GlobeNewsWire
- 2 months ago - NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September - GlobeNewsWire
- 2 months ago - NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New President - GlobeNewsWire
- 2 months ago - NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy - GlobeNewsWire
- 3 months ago - NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas - GlobeNewsWire
- 3 months ago - NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments - GlobeNewsWire
- 3 months ago - NeOnc Technologies Appointments the Honorable Jimmy Delshad to its Board of Directors - GlobeNewsWire